Kami Maddocks
Professor of Hematology, Lymphoma Program Director
Ohio State University · Columbus, United States
Lymphoma researcher at Ohio State with extensive clinical trial experience in MCL and other B-cell lymphomas.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.
Leukemia & lymphoma · Feb 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 24, 2026
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Blood advances · Nov 11, 2025
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.
Journal of the National Comprehensive Cancer Network : JNCCN · Jun 23, 2025
Your chemo is no good here: management of high-risk MCL.
Hematology. American Society of Hematology. Education Program · Dec 6, 2024
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Blood advances · Sep 10, 2024
Does TRIANGLE take down transplantation in mantle cell lymphoma?
Lancet (London, England) · May 25, 2024